The Inhibition and Potentiation of Procarbazine on Hepatic Mixed-Function Oxidases in Pentobarbital Tolerant and Nontolerant Mice

References

• Bollage W., Grunberg E. Tumor inhibitory effects of a new class of cytotoxic agents: Methylhydrazine derivatives. Experientia (Basel) (1963); 19: 130
   PubMedGoogle Scholar
• Kelly G. M., O'Gara G. W., Gadehar K., Yancey S. T., Oliverio V. T. Carcinogenic activity of a new antitumor agent, N‐isopropyl‐α‐(2‐methylhydrazino)‐p‐toluamide, hydrochloride (NSC‐77213). Cancer Chemother. Rep. (1964); 39: 77
   PubMedGoogle Scholar
• Chaube S., Murphy M. L. Fetal malformation produced in rats by N‐isopropyl‐α‐(2‐methylhydrazine)‐p‐toluamide hydrochloride (procarbazine). Teratology (1969); 2: 23
   PubMedGoogle Scholar
• Berneis K., Kobler M., Bollag W., Kaiser A., Langemann A. Degradation of deoxyribonucleic acid by new tumor‐inhibiting compounds ‐ the intermediate formation of hydrogen peroxide. Experientia (Basel) (1963); 19: 132
   PubMedGoogle Scholar
• Sartorelli A. C., Tsunamura S. Studies on the biochemical mode of action of a cytotoxic methyl hydrazine derivative, N‐isopropyl‐α‐(2 methylhydrazine)‐p‐toluamide. Mol. Pharmacol. (1966); 2: 275
   PubMed Web of Science ®Google Scholar
• Weitzel G., Shneider F., Fretzdorff A. M. Cytostatic effect of methyl hydrazines. Experientia (Basel) (1964); 20: 38
   PubMedGoogle Scholar
• Lee I. P., Lucier G. W. The potentiation of barbiturate‐induced narcosis by procarbazine. J. Pharmacol. Exp. Therap. (1976); 196: 586
   PubMed Web of Science ®Google Scholar
• Ho I. K., Yamamoto I., Loh H. H. A model for the rapid development of dispositional and functional tolerance to barbituarates. Eur. J. Pharmacol. (1975); 30: 164
   PubMed Web of Science ®Google Scholar
• Ho I. K. Systematic assessment of tolerance to pentobarbital by pellet implantation. J. Pharmacol. Exp. Therap. (1976); 197: 479
   PubMed Web of Science ®Google Scholar
• Kato R., Gillette J. R. Effect of starvation on NADPH‐dependent enzymes in liver of male and female rats. J. Pharmacol. Exp. Therap. (1965); 150: 279
   Web of Science ®Google Scholar
• Brodie B. B., Burns J. J., Mark L. C., Lief P. A., Bernstein E., Paper E. M. The fate of pentobarbital in man and dog and a method for its estimation in biological material. J. Pharmacol. Exp. Ther. (1953); 109: 26
   PubMed Web of Science ®Google Scholar
• Nash T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J. (1953); 55
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide‐binding pigment of liver microsomes. J. Biol. Chem. (1964); 239: 2370
   PubMed Web of Science ®Google Scholar
• Gillette J. R., Brodie B. B., LaDu B. N. The oxidation of drugs by liver microsomes: On the role of TPNH and oxygen. J. Pharmacol. Exp. Therap. (1957); 119: 332
   Google Scholar
• Williams C. H., Kamin H. Microsomal triphosphopyridine nucleotide‐cytochrome c reductase in liver. J. Biol. Chem. (1962); 237: 587
   PubMed Web of Science ®Google Scholar
• Schenkman J. B., Remmer H., Estabrook E. Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol. Pharmcol. (1967); 3: 113
   PubMed Web of Science ®Google Scholar
• Lowry O., Rosebrough N., Farr A., Randall R. Protein measurement with the Folin phenol reagent. J. Biol. Chem. (1951); 193: 265
   PubMed Web of Science ®Google Scholar
• Conney A. H., Burns J. J. Factors influencing drug metabolism. Advan. Pharmacol. J. (1962); 31
   Google Scholar
• Remmer H. Die Ursache der Gewohnung on oxydable Barbiturates. Naunyn‐Schmiedebergs Arch. Exp. Pathol. Pharmakol. (1963); 244: 311
   PubMedGoogle Scholar
• Kato R., Chiesara E., Vassanelli P. Further studies on the inhibition and stimulation of microsomal drug metabolizing enzymes of rat liver by various compounds. Biochem. Pharmacol. (1964); 13: 69
   PubMed Web of Science ®Google Scholar
• Conney A. H. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. (1967); 19: 317
   PubMed Web of Science ®Google Scholar
• Stevenson I. H., Turnbull M. J. Hepatic drug‐metabolizing enzyme activity and duration of hexobarbitone anesthesia in barbitone‐dependent and withdrawal rats. Biochem. Pharmacol. (1968); 17: 2297
   PubMedGoogle Scholar
• Yamamoto I., Ho I. K., Loh H. H. Acceleration of pentobarbital metabolism in tolerant mice induced by pentobarbital pellet implantation. Life Sciences (1977); 20: 1353
   PubMed Web of Science ®Google Scholar
• Anders M. W., Mannering G. J. Inhibition of drug metabolism. IV. Induction of drug metabolism by 2‐diethylaminoethyl 2,2‐diphenylvalerate‐HCl (SKF 525A) and 2,4‐dichloro‐6‐phenylphenoxyethy‐ diethylamine‐HBr (Lilly 18947) and the effect of induction on the inhibitory properties of SKF 525A type compounds. Mol. Pharmacol. (1966); 2: 341
   PubMed Web of Science ®Google Scholar
• Anders M. W. Enhancement and inhibition of drug metabolism. Annu. Rev. Pharmacol. (1971); 11: 37
   PubMedGoogle Scholar
• Fernandez G., Castro J. A. Induction of rat liver drug metabolizing enzymes by promethazine. Drug Metab. Dispos. (1977); 5: 91
   PubMed Web of Science ®Google Scholar
• Gillette J. R., Sasame H., Stripp B. Mechanisms of inhibition of drug metabolic reactions. Drug. Metab. Dispos. (1973); 1: 164
   PubMed Web of Science ®Google Scholar
• Jenner S., Netter K. J. On the inhibition of microsomal drug metabolism of SKF 525A. Biochem. Pharmacol. (1972); 21: 1921
   PubMed Web of Science ®Google Scholar
• Mannering G. J. Concepts in Biochemical Pharmacology. Handbook of Experimental Pharmacology, B. B. Brodie, J. R. Gillette. Springer‐Verlag, Berlin (1971); 461, Part 2
   Google Scholar
• Schenkman J. B., Wilson B. J., Cinti D. L. Diethylaminoethyl 2,2‐diphenylvalerate‐HCl (SKF 525A). In vivo and in vitro effects of metabolism by rat liver microsomes formation of an oxygenated complex. Biochem. Pharmacol. (1972); 21: 2373
   PubMed Web of Science ®Google Scholar